Elixira
Elixira is a Swedish preclinical-stage company developing a proposed AI-guided nanobot platform for autonomous, single-injection cancer prevention. Founded in 2025, it operates via a licensing model targeting human and veterinary applications, with no revenue or external funding to date.
- Company typePrivate
- Founded2025
- HeadquartersLund, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Elixira does
Elixira is a Swedish preclinical-stage company developing a proposed AI-guided neuromorphic nanobot platform intended for autonomous, lifelong cancer prevention delivered as a single injection. Founded in 2025 in Lund by Tess Fries, who describes herself as having no formal scientific training, the company is targeting a broad set of prospective user segments including oncology treatment centers, high-risk patient populations, vulnerable and elderly patients, veterinary oncology, space and defense health systems, and global health initiatives in low-resource settings. The platform is positioned to operate continuously inside the human body, detecting and eliminating abnormal cells at the subcellular level without external power, devices, or network connectivity.
The core technology is described as a combination of AI-guided diagnostics, subcellular precision intervention, and self-sustaining internal energy harvesting, packaged into a single biocompatible nanobot. Product architecture follows a platform-plus-modules model: Elixira is the core human application, and Elixira Fauna is the veterinary extension for cancer prevention in non-human mammals. The platform is patent-pending with a separate IP track filed for the veterinary extension, and the company has initiated discussions with a leading CRO for preclinical validation and with a leading European CDMO that has reviewed the concept and confirmed buildability using existing manufacturing capabilities. No working prototype, clinical data, or peer-reviewed validation of the platform has been disclosed.
Elixira operates exclusively through a royalty-based licensing model with no direct product sales. Revenue is intended to flow from licensing agreements structured around market, application, and distribution volume, with optional tiered or performance-based royalty structures available. The company is seeking licensing partners with regulatory expertise, ethical alignment, and infrastructure sufficient to advance the platform into clinical development. As of the available data, Elixira has not raised external funding, reports 1–10 employees, and has generated no disclosed revenue.
Elixira firmographics
Firmographics- Name
- Elixira
- Legal name
- Elixira
- Website
- https://elixira.tech
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Elixira is a Swedish preclinical-stage company developing a proposed AI-guided nanobot platform for autonomous, single-injection cancer prevention. Founded in 2025, it operates via a licensing model targeting human and veterinary applications, with no revenue or external funding to date.
- Ownership category
- akta.pro rank
Elixira industry classification
Industry- Product category
- Preventive Nanomedicine
- NAICS
- Research and Development in Nanotechnology (541713)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
- akta.pro secondary industry
- Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)
Keywords
Where Elixira is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Markets served
Elixira business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Others, Marketing or Sales, Operations
Revenue model
- Licensing Royalties: Elixira is licensed through a royalty-based model that ensures long-term value creation for all partners. Royalties are based on clearly defined metrics such as market, application, and distribution volume, creating a transparent framework where each party benefits in proportion to real-world impact and adoption.
- Tiered Royalty Options: Optional models for tiered royalties or performance-based incentives are available based on region, scalability, and strategic alignment.
- Veterinary Licensing (Elixira Fauna): Revenue from veterinary extension of the platform tailored for licensed cancer prevention in non-human mammals including cats, dogs, and horses.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Elixira product offering
Product offeringCore offering
Elixira is an AI-guided neuromorphic nanobot platform for autonomous, lifelong cancer prevention delivered as a single injection. The system combines real-time AI diagnostics, subcellular precision elimination of abnormal cells, self-cleanup, and frictionless internal energy harvesting into one self-sustaining unit that operates continuously without external devices, networks, or maintenance. The platform is offered to strategic licensing partners for human clinical development and is extended to non-human mammals through the Elixira Fauna sub-brand.
Product overview
Elixira operates as a unified platform-plus-modules architecture. The core platform is Elixira — an AI-guided nanobot system for lifelong human cancer prevention delivered via a single injection, integrating autonomous detection, precision elimination, and self-sustaining energy into one cohesive system. Elixira Fauna extends this same core platform to the veterinary domain for cancer prevention in non-human mammals. Both offerings share the same modular architecture, with Elixira Fauna available only under a valid human Elixira license.
Differentiator
Problem solved
Functional benefit
Brands
- Elixira Fauna: The veterinary extension of the core Elixira platform, focused on cancer prevention in non-human mammals including cats, dogs, horses, and other animals. Requires a valid Elixira license for access.
Products and services
- Elixira Platform The Elixira platform is a fully autonomous, AI-guided neuromorphic nanobot system designed for lifelong cancer prevention across all cancer types. Delivered as a single injection, it integrates deep AI diagnostics, autonomous subcellular precision elimination of abnormal cells, and frictionless internal energy harvesting into one self-sustaining unit that operates continuously without external devices, networks, or maintenance. Offered to strategic licensing partners for human clinical development under tailored territorial and ethical licensing agreements.
- Elixira Fauna Elixira Fauna is the veterinary extension of the Elixira core platform, tailored for cancer prevention in non-human mammals including cats, dogs, horses, and other animals. It uses the same modular AI-guided nanobot architecture as the human platform and is available only with a valid Elixira license, licensed separately to veterinary partners, animal health organizations, livestock operators, and conservation groups.
Quantifiable outcome
- Global cancer care market opportunity exceeds $6 trillion annually
- +2 more outcomes
Companies that use Elixira
Customer profileNamed customers1 record
Segments6 records
Ideal customer profiles3 records
Elixira technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature10 records
Elixira partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Leading European CDMOcoreA leading European CDMO (Contract Development and Manufacturing Organization) firm has reviewed Elixira and confirmed that the platform is buildable using their scientific and manufacturing capabilities. They have expressed interest in supporting the development as a contract research and manufacturing partner to help bring Elixira to clinical application.
- Leading CROcoreElixira has initiated discussions with a leading CRO (Contract Research Organization) to define collaboration and technical frameworks, aiming to validate safety, feasibility, and manufacturability within regulatory standards. The company is preparing for preclinical development phase.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Elixira competitors and assessment
Company assessmentDirect peers
- MagForce AG: German nanomedicine company developing nanoparticle-based thermal therapy for brain and prostate cancers. Directly comparable as a clinical-stage nanomedicine oncology platform.
- Nanospectra Biosciences: US company developing AuroLase therapy, a nanoshell-based targeted thermal ablation for solid tumors. Comparable as a nanoparticle-driven cancer therapy developer.
- Selecta Biosciences: Clinical-stage company using synthetic nanoparticle immunomodulatory particles for cancer and autoimmune disease. Comparable in applying engineered nanocarriers to oncology.
- Starpharma: Australian-listed company developing dendrimer-based nanopharmaceuticals including DEP drug delivery and VivaGel. Comparable as a nanomedicine platform with multiple therapeutic programs.
- NanoTherapeutics: Developer of nano-formulated pharmaceuticals targeting infectious disease and cancer. Comparable as a nanotechnology reformulation play in oncology adjacent areas.
- CytImmune Sciences: Clinical-stage company developing tumor-targeted nanoparticle delivery of chemotherapeutics (Aurimune). Comparable as a targeted nanomedicine oncology developer.
Emerging players
- CEL-SCI Corporation: Clinical-stage cancer immunotherapy developer with novel delivery platforms. Comparable as a smaller oncology platform company working on differentiated delivery technology.
- BIND Therapeutics: Pioneer in Accurin polymeric nanoparticle therapeutics for oncology (acquired by Pfizer). Comparable as a nanoparticle-engineered targeted cancer therapy platform.
Broad incumbents
- Merck KGaA: Diversified life sciences company with significant nanomedicine and oncology operations including the Sigma-Aldrich life science portfolio. Comparable as a potential licensing partner with global reach and regulatory expertise.
- AbbVie: Global biopharmaceutical company with a large oncology franchise and active licensing/business development function. Comparable as a potential strategic partner for an early-stage oncology platform.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat4 records
Key risks7 records
Key highlights5 records
Customer concentration
Elixira social profiles
Digital presenceElixira financial estimates
Financial estimateRevenue estimate
Valuation estimate
Elixira leadership team
Management profileNumber of profiles
Profiles1 record
Elixira subsidiaries and ownership
Company hierarchySubsidiaries1 record
Elixira funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Elixira M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Elixira
What does Elixira do?
Elixira is an AI-guided neuromorphic nanobot platform for autonomous, lifelong cancer prevention delivered as a single injection. The system combines real-time AI diagnostics, subcellular precision elimination of abnormal cells, self-cleanup, and frictionless internal energy harvesting into one self-sustaining unit that operates continuously without external devices, networks, or maintenance. The platform is offered to strategic licensing partners for human clinical development and is extended to non-human mammals through the Elixira Fauna sub-brand.
Is Elixira a public or private company?
Elixira is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Elixira founded?
Elixira was founded in 2025. It employs 1 to 10 people.
Where is Elixira based?
Elixira is headquartered in Lund, Sweden, in the Europe region.
How does Elixira make money?
Three revenue lines are on record. Licensing Royalties are the primary driver. The others are tiered Royalty Options and veterinary Licensing (Elixira Fauna).
Who are Elixira's main competitors?
Direct peers on record are MagForce AG, Nanospectra Biosciences, Selecta Biosciences, Starpharma, NanoTherapeutics and CytImmune Sciences. Emerging players are CEL-SCI Corporation and BIND Therapeutics. Broad incumbents are Merck KGaA and AbbVie.
Does Elixira have an API?
No public API is recorded for Elixira.
What industry is Elixira in?
Elixira's product category is Preventive Nanomedicine. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish). Its NAICS code is 541713 and its SIC code is 2834.